Related Experiment Video
Updated: Dec 11, 2025
07:35
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
789
Non-Convulsive Status Epilepticus in Behavioral Variant Frontotemporal Dementia
Adrián Valls-Carbó1, Vicente Gajate1, María Romeral1
1Department of Neurology, Hospital Clinico San Carlos, Health Research Institute "San Carlos" (IdISCC), Universidad Complutense de Madrid, Madrid, Spain.
Journal of Alzheimer'S Disease : JAD
|August 18, 2020
Summary
Epilepsy is less common in frontotemporal dementia (FTD) than Alzheimer's disease. This study presents two cases of non-convulsive status epilepticus in FTD, emphasizing its importance in diagnosis.
Area of Science:
- Neurology
- Neuroscience
- Geriatric Medicine
Background:
- Epilepsy is infrequently diagnosed in patients with frontotemporal dementia (FTD) compared to Alzheimer's disease.
- Behavioral variant frontotemporal dementia (bvFTD) is a common subtype of FTD, characterized by prominent behavioral and personality changes.
Observation:
- This report details two cases of non-convulsive status epilepticus (NCSE) in patients diagnosed with behavioral variant frontotemporal dementia.
- In the first case, NCSE presented as the initial symptom, manifesting as mutism and loss of consciousness.
- In the second case, NCSE occurred one year post-diagnosis, coinciding with a significant clinical decline.
Findings:
- The findings suggest that non-convulsive status epilepticus can be an early or complicating feature of frontotemporal dementia.
- These cases highlight a potential underestimation of epilepsy prevalence in FTD.
Implications:
- The study underscores the necessity of considering NCSE in the differential diagnosis for patients presenting with new-onset seizures, particularly those with FTD.
- Early recognition and management of NCSE in FTD may improve patient outcomes and diagnostic accuracy.
More Related Videos
Related Concept Videos
01:13Seizures: Classification
1.1K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.1K
01:24Epilepsy and Seizures: Overview
1.0K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
01:30Electroconvulsive Therapy
506
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
506
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
686
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
686